J Clin Neurol.  2014 Jan;10(1):24-31.

Clinical and Pathological Features of Korean Patients with DNM2-Related Centronuclear Myopathy

• Park YE
• Choi YC
• Bae JS
• Lee CH
• Kim HS
• Shin JH
• Kim DS

Abstract

BACKGROUND AND PURPOSE
Centronuclear myopathy (CNM) is characterized by the presence of central nuclei within a large number of muscle fibers. Mutations of the dynamin 2 gene (DNM2) are common causes of autosomal dominant or sporadic CNM. The aim of this study was to characterize the clinical and pathological features of CNM relative to the presence of DNM2 mutations.
METHODS
Six patients with clinical and pathological features of CNM were recruited. Detailed clinical and pathological findings were analyzed according to the presence of DNM2 mutations.
RESULTS
We detected DNM2 mutations in four of the six sporadic CNM patients, and identified the following distinct clinical and pathological features in those patients with DNM2 mutations: preferential involvement of the distal lower limbs, typical nuclear centralization, and radially distributed sarcoplasmic strands in muscle pathology. In contrast, those without DNM2 mutations exhibited rather diffuse muscular involvement, and nuclear internalization and myofibrillar disorganization were more pronounced features of their muscle pathology.
CONCLUSIONS
These findings suggest the presence of specific features in Korean CNM patients. A detailed clinical and pathological examination of CNM patients would be helpful for molecular genetic analyses of this condition.

Keyword

centronuclear myopathy; DNM2; muscle involvement; central nuclei; internal nuclei; sarcoplasmic strands

MeSH Terms

Dynamin II
Humans
Lower Extremity
Molecular Biology
Muscles
Myopathies, Structural, Congenital*
Pathology
Dynamin II

Figure

• 

  Fig. 1 Muscle CT scans of patients 1, 4, and 6. In patient 1, the rectus femoris and biceps femoris were mildly atrophied (arrowheads, A), while the posterior compartment of the lower legs was the most preferentially involved (arrows, B). The hip girdle muscles in patient 1 were somehow affected (C). In patient 4, muscles in the posterior lower legs were more prominently atrophied (arrows, E) and the biceps femoris and vasti muscles were also affected (arrowheads, D); however, the hip girdle muscles were relatively spared (F). In patient 6, the muscles in the thighs (G), lower legs (H), and hip girdle (I) were evenly atrophied.

• 

  Fig. 2 Muscle pathology in patients 1 and 4. In patient 1, most of the nuclei were placed in the center of the muscle fibers in hematoxylin and eosin (H&E) staining (A), a nuclear chain was highlighted in a longitudinal H&E-stained section (B), and sarcoplasmic strands were radially arranged in nicotinamide adenine dinucleotide dehydrogenase-tetrazolium reductase (NADH-TR) staining (C). In patient 4, most of the nuclei were centrally placed in H&E staining (D), and radial arrangement of the sarcoplasmic strands and nonreactive regions for the enzyme were demonstrated in NADH-TR staining (E). Accumulation of stain and peripheral halos were observed in some fibers (arrows in E). Electron microscopic observation revealed a central nucleus and radial arrangement of strands in patient 4 (F).

• 

  Fig. 3 Muscle pathology in patients 5 and 6. In patient 5, nuclear centralization and internalization were mostly found in the small fibers in H&E staining (A), and nonreactive regions for NADH-TR were observed in some fibers (B). With myofibrillar ATPase stain (pH 10.7), type I fiber atrophy and predominance was noted in patient 5, mimicking the pattern of congenital fiber type disproportion (C). In patient 6, nuclear centralization and internalization were noted, and multiple internal nuclei appeared frequently in H&E staining (D), an abnormal pattern of staining was absent in NADH-TR staining (E), and type 1 fiber predominance was noted in ATPase staining (F; pH 10.7). Radial arrangement of sarcoplasmic strands was not observed around a central nucleus (G), but small areas of myofibrillar disorganization were detected (H) in muscle biopsy tissue from patient 6 in electron microscopy. NADH-TR: nicotinamide adenine dinucleotide dehydrogenase-tetrazolium reductase, ATPase: adenosine triphosphotase.

Reference

1. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol. 1966; 14:1–14.

2. Laporte J, Hu LJ, Kretz C, Mandel JL, Kioschis P, Coy JF, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet. 1996; 13:175–182.

3. Bitoun M, Maugenre S, Jeannet PY, Lacène E, Ferrer X, Laforêt P, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet. 2005; 37:1207–1209.

4. Nicot AS, Toussaint A, Tosch V, Kretz C, Wallgren-Pettersson C, Iwarsson E, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet. 2007; 39:1134–1139.

5. Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol. 2010; 68:717–726.

6. Züchner S, Noureddine M, Kennerson M, Verhoeven K, Claeys K, De Jonghe P, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet. 2005; 37:289–294.

7. Jeannet PY, Bassez G, Eymard B, Laforêt P, Urtizberea JA, Rouche A, et al. Clinical and histologic findings in autosomal centronuclear myopathy. Neurology. 2004; 62:1484–1490.

8. Melberg A, Kretz C, Kalimo H, Wallgren-Pettersson C, Toussaint A, Böhm J, et al. Adult course in dynamin 2 dominant centronuclear myopathy with neonatal onset. Neuromuscul Disord. 2010; 20:53–56.

9. Bitoun M, Durieux AC, Prudhon B, Bevilacqua JA, Herledan A, Sakanyan V, et al. Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. Hum Mutat. 2009; 30:1419–1427.

10. Susman RD, Quijano-Roy S, Yang N, Webster R, Clarke NF, Dowling J, et al. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscul Disord. 2010; 20:229–237.

11. Böhm J, Biancalana V, Dechene ET, Bitoun M, Pierson CR, Schaefer E, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat. 2012; 33:949–959.

12. Koutsopoulos OS, Koch C, Tosch V, Böhm J, North KN, Laporte J. Mild functional differences of dynamin 2 mutations associated to centronuclear myopathy and Charcot-Marie Tooth peripheral neuropathy. PLoS One. 2011; 6:e27498.

13. Fischer D, Herasse M, Bitoun M, Barragán-Campos HM, Chiras J, Laforêt P, et al. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain. 2006; 129:1463–1469.

14. Catteruccia M, Fattori F, Codemo V, Ruggiero L, Maggi L, Tasca G, et al. Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscul Disord. 2013; 23:229–238.

15. Bitoun M, Bevilacqua JA, Prudhon B, Maugenre S, Taratuto AL, Monges S, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol. 2007; 62:666–670.

16. Hanisch F, Müller T, Dietz A, Bitoun M, Kress W, Weis J, et al. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. J Neurol. 2011; 258:1085–1090.

17. Romero NB. Centronuclear myopathies: a widening concept. Neuromuscul Disord. 2010; 20:223–228.

18. Bevilacqua JA, Bitoun M, Biancalana V, Oldfors A, Stoltenburg G, Claeys KG, et al. "Necklace" fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy. Acta Neuropathol. 2009; 117:283–291.

19. Mori-Yoshimura M, Okuma A, Oya Y, Fujimura-Kiyono C, Nakajima H, Matsuura K, et al. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2. Clin Neurol Neurosurg. 2012; 114:678–683.